智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称“新华制药”或“本公司”)收到国家药品监督管理局核准签发的缬沙坦胶囊(以下简称“本品”)《药品注册证书》。
新华制药申报的缬沙坦胶囊于2025年12月获得药品注册证书，有利于丰富公司治疗心血管疾病产品系列，提升公司综合竞争力。
智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称“新华制药”或“本公司”)收到国家药品监督管理局核准签发的缬沙坦胶囊(以下简称“本品”)《药品注册证书》。
新华制药申报的缬沙坦胶囊于2025年12月获得药品注册证书，有利于丰富公司治疗心血管疾病产品系列，提升公司综合竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.